Required Elements for Next-generation Prognostic Index beyond Left Ventricular Ejection Fraction in Heart Failure
Article Sidebar
Main Article Content
Abstract
Many reports are showing no differences in prognosis between patients with Heart Failure (HF) with preserved and reduced ejection fraction. All-in-one analysis with a multivariable model, including clinical characteristics, blood test, comorbidity, and echocardiographic indices, on clinical outcomes in patients with HF has not been performed rarely in previous studies. We have to accept the need to be more comprehensive in the outcome analysis of patients with HF and consider the intricate interplay of multiple variables in patient outcomes.
Article Details
Copyright (c) 2024 Hoshida S.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Cardiology and Cardiovascular Medicine is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Cardiology and Cardiovascular Medicine is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17:559-573. Available from: https://doi.org/10.1038/s41569-020-0363-2
Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation. 2016;134:73-90. Available from: https://doi.org/10.1161/circulationaha.116.021884
Omote K, Verbrugge FH, Borlaug BA. Heart failure with preserved ejection fraction: Mechanisms and treatment strategies. Annu Rev Med. 2022;73:321-337. Available from: https://doi.org/10.1146/annurev-med-042220-022745
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574-1585. Available from: https://doi.org/10.1002/ejhf.813
Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol. 2014;113:691-6. Available from: https://doi.org/10.1016/j.amjcard.2013.11.014
Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D, et al. Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: Data from the EMPA-REG OUTCOME trial. J Card Fail. 2021;27:888-895. Available from: https://doi.org/10.1016/j.cardfail.2021.05.012
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. Available from: https://doi.org/10.1056/nejmoa1409077
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-1620. Available from: https://doi.org/10.1056/nejmoa1908655
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-1461. Available from: https://doi.org/10.1056/nejmoa2107038
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-128. Available from: https://doi.org/10.1056/nejmoa2030183
Pandey AK, Dhingra NK, Hibino M, Gupta V, Verma S. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9:942-946. Available from: https://doi.org/10.1002/ehf2.13805
Bayes-Genis A, Pascual-Figal D, Nunez J. The pre-HFpEF stage: a new entity that requires proper phenotyping for better management. Eur J Prev Cardiol. 2021;28:935-936. Available from: https://doi.org/10.1177/2047487320902326
Sotomi Y, Hikoso S, Komukai S, Sato T, Oeun B, Kitamura T, et al. OCVC-Heart Failure Investigator. Phenotyping of acute decompensated heart failure with preserved ejection fraction. Heart. 2022;108:1553-1561. Available from: https://doi.org/10.1136/heartjnl-2021-320270
Burke MA, Katz DH, Beussink L, Selvaraj S, Gupta DK, Fox J, Chakrabarti S, Sauer AJ, Rich JD, Freed BH, Shah SJ. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7:288-299. Available from: https://doi.org/10.1161/circheartfailure.113.000854
Hoshida S, Tachibana K, Shinoda Y, Minamisaka T, Yamada T, Higuchi Y, et al. Osaka Cardiovascular Conference Investigators. Left atrial pressure overload and prognosis in elderly patients with heart failure and preserved ejection fraction: A prospective multicenter observational study. BMJ Open. 2021;11. Available from: https://doi.org/10.1136/bmjopen-2020-044605
Hoshida S. Left-side pressure index for all-cause mortality in older adults with HFpEF: Diagnostic potential for HFpEF and possible view for HFrEF. J Clin Med. 2023;12:802. Available from: https://doi.org/10.3390/jcm12030802
Hoshida S. Due diligence of a diastolic index as a prognostic factor in heart failure with preserved ejection fraction. J Clin Med. 2023;12:6692. Available from: https://doi.org/10.3390/jcm12206692